Thijs Isabeau, Siegelaar Sarah E, Elhenawy Yasmine I, Benhalima Katrien, Pinhas-Hamiel Orit, van den Heuvel Tim, Castañeda Javier, Cohen Ohad
Medtronic Diabetes, Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Diabetes Obes Metab. 2026 Jan;28 Suppl 1(Suppl 1):35-48. doi: 10.1111/dom.70377. Epub 2026 Jan 2.
Sex-based disparities in the incidence, prevalence and disease manifestations have been observed across various medical conditions, including type 1 diabetes (T1D). Differences in glycaemic control and quality of life between men and women have been reported, with women experiencing lower rates of glycaemic targets and a higher risk for long-term complications, particularly cardiovascular disease. Additionally, women face a greater economic and mental health burden related to T1D. This narrative review explores the challenges that complicate glycaemic management in women living with T1D, including hormonal influences during puberty, pregnancy and the (peri-) menopausal period. We also summarize current available evidence on the safety and efficacy of the MiniMed™ 780G (MM780G) system in addressing these challenges for women living with T1D. Finally, recent real-world data are reported on the absence of significant sex-related differences in glycaemic outcomes of over 280 000 real-world users of the MM780G, across various age groups from childhood and adolescence to the (peri-) menopausal period.
在包括1型糖尿病(T1D)在内的各种疾病中,均观察到了基于性别的发病率、患病率和疾病表现差异。有报告称,男性和女性在血糖控制和生活质量方面存在差异,女性达到血糖目标的比率较低,发生长期并发症尤其是心血管疾病的风险较高。此外,女性面临着与T1D相关的更大经济和心理健康负担。这篇叙述性综述探讨了使T1D女性血糖管理复杂化的挑战,包括青春期、孕期和(围)绝经期的激素影响。我们还总结了目前关于美敦力780G(MM780G)系统在应对T1D女性这些挑战方面的安全性和有效性的现有证据。最后,报告了最近的真实世界数据,即超过280000名MM780G的真实世界使用者,从儿童期、青春期到(围)绝经期的各个年龄组,在血糖结果方面不存在显著的性别差异。